Viracta grants NantKwest exclusive, worldwide rights to develop and commercialize VRx-3996 in combination with its portfolio of natural killer (NK) cell therapies

Viracta Therapeutics Inc.

U.S. / Private Biopharma

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

NantKwest Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

$288.3m on 03/31/2017 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced